Manitoba's Immunization Program: Vaccines Offered Free-of-Charge
(Eligibility Criteria for Publicly-Funded Vaccines)

Updated September 2024

Vaccines listed here are provided free-of-charge to individuals who are registered with Manitoba Health (MH) and for those who are part-way through an immunization series started in another province or territory as part of a publicly-funded program (pending product availability). MH covers all costs associated with administering a publicly-funded vaccine (e.g. physician fees).

Uninsured visitors such as those who live, work and/or study in Manitoba for an extended period and who are not registered with MH can obtain a publicly-funded vaccine if the health care provider determines there to be a public health need. Public health need could mean outbreaks, pandemics, seasonal influenza or exposure to a vaccine preventable disease that may put a susceptible client at increased risk of illness while they are in Manitoba. The vaccine is to be provided free-of-charge using provincial supply but administration fees may still apply. Whenever possible visitors should obtain their immunizations prior to arriving in Manitoba.

Publicly-funded vaccines can only be obtained from the Provincial Vaccine Warehouse by an immunization provider (or delegate) who is registered with MH. Immunization providers can order vaccines by completing MH’s Vaccines and Biologics Order Form. Publicly-funded vaccines are provided to health care providers for the sole purpose of administering MH’s Immunization Program.

Individuals who do not receive a publicly-funded vaccine when it is first recommended are eligible to receive the vaccine at a later time (unless otherwise stated). This is commonly referred to as, ‘once eligible, always eligible.’

MH does not cover the costs for vaccines for TRAVEL, OCCUPATIONAL HEALTH or EDUCATIONAL PURPOSES, with the exception of the following vaccines:

  • For occupational health purposes:
    • Rabies vaccine;
    • Mumps, measles and rubella (MMR) vaccine;
    • Seasonal influenza vaccine.
  • For travel purposes:
    • Children aged 6 months to under 12 months travelling to a measles-endemic country are eligible for one additional dose of mumps, measles and rubella (MMR) vaccine.

MH does not reimburse individuals who pay out-of-pocket for a vaccine that is offered free-of-charge.

Additional doses of a vaccine that are given outside of MH's publicly-funded, recommended immunization series are provided free-of-charge to individuals with certain high-risk medical conditions, as well as to individuals with an inadequate immune response post-immunization (up to one additional series), as determined by a health care provider in consultation with the vaccine-specific recommendations of the Canadian Immunization Guide.

For more detailed information about vaccine schedules, please refer to parts 3 and 4 of the Canadian Immunization Guide (CIG).

The list of vaccines offered free-of-charge (as per below) are subject to change as determined by MH. Check MH's Recommended Immunization Schedule for Infants, Children and Adults for more information about when routine immunizations should be given.

Vaccines provided free-of-charge for outbreak management and control of communicable diseases are listed in MH's Communicable Disease Management ProtocolsManual and/or as determined by a provincial Medical Officer of Health.

COVID-19 Vaccine
Diphtheria, Tetanus Toxoid, acellular Pertussis, Inactivated Polio, Haemophilus influenza type b - paediatric (DTaP-IPV-Hib)
  • All children from 2 months of age to < 7 years of age
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Hypo- or asplenic (Sickle Cell Disease, etc.)
  • Note: DTaP-IPV was previously used in children from 4 years of age to < 7 years who had been not previously immunized as part of their primary series. DTaP-IPV is no longer available for use in Canada once current stock is depleted. DTaP-IPV-Hib is to be used in its place. Please refer to the Recommended Immunization Schedules for those Not Previously Immunized. (www.gov.mb.ca/health/publichealth/cdc/div/not.html)
Haemophilus influenza type b (Hib)
  • Children from 2 months of age to < 5 years of age (up to 59 months).
  • Individuals ≥ 5 years of age with at least one of the following high-risk medical conditions are eligible to receive 1 dose regardless of Hib immunization history, at least one year after any previous dose:
    • Asplenia or hyposplenism
    • Cochlear implant recipients
    • Congenital immune deficiencies (B cell deficiency, T cell mixed defects, phagocytic and neutrophil disorders, complement deficiency)
    • Hemoglobinopathies
    • HIV-infection
    • Hematopoietic stem cell transplant recipients and solid organ transplant recipients (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Hypo- or asplenic (Sickle Cell Disease, etc.)
Hepatitis A (HA)
  • Individuals ≥ 6 months with at least one of the following high-risk medical conditions are eligible to receive 2 doses (refer to Table 1: Dosages and Schedules for Hepatitis A-containing Vaccines of the Canadian Immunization Guide):
    • Chronic renal disease or undergoing dialysis
    • Chronic liver disease including people infected with hepatitis C and chronic hepatitis B carriers
    • Non-malignant hematologic disorders including repeated replacement of plasma-derived clotting factors
    • HIV-infection
    • Hematopoietic stem cell transplantation (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • Solid organ transplant candidates and recipients with chronic liver diseases (prior to transplant or 6 months post-transplant)
    • Congenital immune deficiencies (B cell deficiency, T cell mixed defects, phagocytic and neutrophil disorders, complement deficiency)
  • Individuals with life-style risks for infection, including people engaging in illicit drug use and men having sex with men (MSM).
Hepatitis B (HB)
  • All children born on or after January 1st 2006 in Grade 6 (school-based program) are eligible to receive 2 doses of: Recombivax HB® 1.0mL at 0, 4-6 months OR Engerix®-B 1.0mL at 0, 6 months.
  • Individuals born between 1989 and 2005 who missed the vaccine in Grade 4 (school-based program) are eligible for up to 4 doses; 3 or 4 doses are recommended for individuals 16 years of age and older.*
  • Individuals of any age with at least one of the following high-risk medical conditions are eligible to receive 3 or 4 doses:*
    • Chronic liver disease from any cause, including persons infected with hepatitis C.
    • Hemophiliacs and other people receiving repeated infusions of blood or blood products.
    • Chronic renal disease or undergoing chronic dialysis (hemodialysis or peritoneal dialysis).
    • Congenital immune deficiencies (B cell deficiency, T cell mixed defects, phagocytic and neutrophil disorders, complement deficiency).
    • HIV-infection.
    • Hematopoietic stem cell transplant recipient (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule) or awaiting solid organ transplant.
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Hypo- or asplenic (Sickle Cell Disease, etc.)
  • Inmates of correctional facilities.*
  • Residents of institutions for the developmentally challenged.*
  • Individuals with lifestyle risks for infection, including people engaging in illicit drug use, men having sex with men (MSM) and those who engage in other risky sexual practices.*
  • Premature and/or full-term infants of mothers who are hepatitis B surface antigen (HBsAg) positive or unknown HBsAg status are eligible for up to 4 doses.**

*Refer to Table 3: Recommended Dosages and Schedules for Hepatitis B-Containing Vaccines of the Canadian Immunization Guide for product-specific recommendations by age/medical condition.

**Refer to Table 3: Recommended Dosages and Schedules for Hepatitis B-Containing Vaccines as well as Table 4: Hepatitis B Recommendations for Premature Infants Weighing less than 2,000 grams, by Maternal Hepatitis B Surface Antigen (HBsAg) Status of the Canadian Immunization Guide for vaccine dosage, interval and schedule recommendations.

Hepatitis A & B (HAHB)
  • HAHB may be made available to individuals meeting the criteria for both hepatitis A and B immunizations, provided the individual is still susceptible to both hepatitis A and hepatitis B viruses (i.e. no prior infection with hepatitis A or B, no prior immunization with hepatitis A or B).
Human Papillomavirus (HPV)
  • Healthy females born on or after January 1, 1997 and healthy males born on or after January 1, 2002 are eligible to receive the HPV vaccine, routinely provided as part of the  grade 6 school-based immunization program.
  • For healthy females and males 11 to less than15 years of age, 2 doses are recommended. For those who are 15 years of age and older, a 3-dose schedule is recommended, unless the first dose of vaccine was administered before the age of 15.
  • Individuals with at least one of the following high-risk criteria are eligible to receive up to 3 doses:
    • Immunocompetent HIV-infected males 9-26 years of age and females 9-45 years of age.
    • Males 9-26 years of age and females 9-45 years of age who have congenital immune deficiencies (B cell deficient, T cell mixed defects, phagocytic and neutrophil disorders, complement deficiency) or acquired immune deficiencies (pre-solid organ transplant or post-solid organ transplants, hematopoietic stem cell transplant recipients, as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule).
    • Males ≤ 18 years of age who are, or who have ever been, incarcerated.
    • Individuals who are currently, or who have previously been, diagnosed with recurrent respiratory papillomatosis.
    • Males 9-26 years of age who identify as gay or bisexual
    • Transgender males and transgender females 9-26 years of age.
    • Females 9-45 years of age who have a newly diagnosed high-grade cervical histopathology result.
    • Males 9-26 years of age and females 9-45 years of age who are victims of sexual assault.  
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
      1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemotherapy or radiation therapy, or
      2. Hypo- or asplenic (Sickle Cell Disease, etc.)

For minimum intervals between doses of HPV vaccine, please see the Canadian Immunization Guide.

Inactivated Polio Virus (IPV)
  • Children < 18 years of age who are unimmunized or incompletely immunized1.
  • Hematopoietic stem cell transplant recipients (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule). 
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Hypo- or asplenic (Sickle Cell Disease, etc.)

1 Unimmunized: Individuals lacking adequate documentation of IPV immunization should be considered unimmunized and started on an immunization schedule appropriate for their age and risk factors.

Incompletely immunized: Individuals who have received only OPV vaccine after April 1, 2016 without following receipt of at least two doses of IPV, should receive IPV-containing vaccine according to the Immunization Schedule for Individuals Not Previously Immunized.

Measles, Mumps, Rubella (MMR)
  • All children ≥ 12 months of age are eligible to receive 2 doses. In addition to those doses, children age 6 months to under 12 months are eligible for 1 dose if travelling to a measles endemic country.
  • All adults born in or after 1985 are eligible to receive 2 doses of the MMR vaccine.
  • Adults born between 1970 and 1984 are eligible to receive one dose if they do not have documentation of receiving one dose of an MMR vaccine or a history of a laboratory-confirmed infection or laboratory evidence of immunity*.
  • Health care workers are eligible for 2 doses of MMR vaccine regardless of year of birth if they do not have documentation of receiving two doses of MMR vaccine or a history of a laboratory-confirmed infection or laboratory evidence of immunity*.
  • Students born before 1970 are eligible for 1 dose; and Students born in or after 1970 are eligible for 2 doses of MMR vaccine if they do not have documentation of receiving an MMR vaccine or a history of a laboratory-confirmed infection or laboratory evidence of immunity*.
  • Hematopoietic stem cell transplantation (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have been provided a CCMB directed Immunization Schedule.

*Note: Ordering measles, mumps or rubella serology is not necessary prior to administering an MMR vaccine.

  • If the client does not have previous serology demonstrating immunity AND does not have documentation of receiving the recommended number of doses of the MMR vaccine or previous laboratory-confirmed infection, assume that they are not immune and administer a dose of the MMR vaccine.
  • If serology is inadvertently done after receiving MMR immunization(s) and does not demonstrate measles or mumps immunity, re-immunization is not necessary.
  • If previous serology is available and shows the client is not immune against rubella only, they can receive one dose of MMR and will be considered immune if the dose was administered after their first birthday.

**Note: Adults born before 1970 are generally considered immune to measles, mumps and rubella due to previous exposure to these infections. They are not eligible for any doses of MMR vaccines unless they are a health care worker or a student.

Measles, Mumps, Rubella, Varicella (MMRV)
  • Individuals 12 years of age and under:*
    • meeting the eligibility criteria for both mumps, measles, and rubella (MMR) and varicella (Var) immunizations. 

*As per Health Canada, the MMRV vaccine is NOT approved in individuals ≥13 years of age.

Meningococcal Conjugate (Men-C-ACYW)
  • 12 month program
    • Individuals born on or after January 1, 2020 are eligible to receive a dose regardless of previous Men-C-C immunization history if they are at least 12 months old but < 10 years old*.
    • Individuals born between Jan 1, 2008 and December 31, 2019 are eligible to receive a dose IF they never received a dose of Men-C-C vaccine as part of the 12 month program AND are < 10 years old.
  • School-based immunization program
    • Individuals born on or after January 1, 2008 are eligible to receive a dose at ≥10 years of age, routinely offered in Grade 6, regardless of Men-C-C or Men-C-ACYW immunization history.
    • Individuals born between 1995 and 2007 are eligible to receive a dose if they have no previous history of receiving a Men-C-C vaccine.
  • Individuals with at least one of the following high-risk medical conditions (more than one dose may be required, please see below for more information†):
    • Anatomic or functional asplenia (including sickle cell disease)
    • Complement, properdin, factor D or primary antibody deficiency
    • Persons with acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab (Soliris™)
    • Certain genetic risk factors (e.g. polymorphisms in the genes for mannose-binding lectin and tumor necrosis factor)
    • HIV-infection
    • Hematopoietic stem cell transplantation (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • Solid organ transplantation
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
      1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
      2. Hypo- or asplenic (Sickle Cell Disease, etc.)

* If previously immunized with Men-C-C, a minimum of 4 weeks is recommended prior to receipt of Men-C-ACYW.

Meningococcal Type B (4CMenB)
  • Individuals 2 months to ≤ 25 years of age with at least one of the following high-risk medical conditions:
    • anatomic or functional asplenia (including sickle cell disease)
    • Solid organ transplantation
    • congenital complement, properdin, factor D or primary antibody deficiencies
    • acquired complement deficiencies
    • human immunodeficiency virus (HIV)
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
      1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
      2. Hypo- or asplenic (Sickle Cell Disease, etc.)
  • Two or three doses are required, depending on the age at first dose:
Age at series initiation # of doses Schedule
2 to 5 months 2+1 1st dose
2nd dose, 2 months after 1st dose
3rd dose
booster, between 12 and 23 months of age (as early as possible in the second year of life is preferred) and at least 6 months after 2nd dose
6 to 11 months 3 1st dose
2nd dose, 2 months after 1st dose
3rd dose (booster), at least 2 months after 2nd dose and ≥12 months of age
12 months to 23 months 2 1st dose
2nd dose, 2 months after 1st dose
2 to 25 years 2 1st dose
2nd dose, 1 month after 1st dose

For information on outbreak control, call the regional Medical Officer of Health (MOH).

Pneumococcal Vaccines
  • Pneumococcal Conjugate Vaccine (Pneu-C-15)
    • Children 2 months to ≤ 23 months of age are eligible to receive 3 doses (2, 4 and 12 months of age). If a schedule was started with Pneu-C-13, it does not need to be repeated and can be completed with Pneu-C-15.
    • Children 24 months to ≤ 59 months of age are eligible to receive 1 dose if previously unimmunized or to finish a vaccination schedule started with any pneumococcal conjugate vaccine.

    Note: Children who are high risk for invasive pneumococcal disease are eligible to receive Pneu-C-20. Please see the eligibility criteria for Pneu-C-20 below.

  • Pneumococcal Conjugate Vaccine (Pneu-C-20)

    • Note: Individuals 2 years and older who are at high risk of invasive pneumococcal disease and have already received a dose of Pneu-C-20 are not recommended to receive a second dose of Pneu-C-20.


    Children

    • Children 2 months to ≤ 23 months of age at high risk of invasive pneumococcal disease* are eligible to receive 4 doses (2, 4, 6 and 18 months of age). If a schedule was started with Pneu-C-13, it does not need to be repeated and can be completed with Pneu-C-20.
    • Children 2 months to ≤ 23 months of age living in First Nations communities are eligible to receive 4 doses (2, 4, 6 and 18 months of age). If a schedule was started with Pneu-C-13, it does not need to be repeated and can be completed with Pneu-C-20.
    • Children 24 months to ≤ 17 years of age at high risk of invasive pneumococcal disease* are eligible to receive 1 dose (at least 8 weeks after any previous dose of Pneu-C-13 vaccine or 5 years after any previous dose of Pneu-P-23, whichever is longer).

    Adults

    • All individuals ≥ 65 years of age are eligible to receive 1 dose if they have not yet received Pneu-P-23 since turning 65 years old. (Note: There is currently no recommendation to administer a dose of Pneu-C-20 if someone has already received a dose of Pneu-C-20 before turning 65.) If they had received a dose of Pneu-P-23 before turning 65, Pneu-C-20 can be administered 5 years after that dose.
    • Adults 18 to 64 years of age at high risk of invasive pneumococcal disease* are eligible to receive 1 dose (at least 8 weeks after any previous dose of Pneu-C-13 vaccine or 5 years after any previous dose of Pneu-P-23, whichever is longer).
    • Individuals 65 years and older have the following medical conditions are eligible for one dose (at least 5 years after any previous dose of Pneu-P-23 vaccine):

    All Ages

    • Patients currently under the care of a haematologist or oncologist from Cancer Care Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
      1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemotherapy or radiation therapy, or
      2. Hypo- or asplenic (Sickle Cell Disease, etc.)

      *The high-risk criteria are as follows:

      • Chronic cerebral spinal fluid (CSF) leak
      • Chronic neurologic condition that may impair clearance of oral secretions
      • Cochlear implants (including those children who are to receive implants)
      • Chronic cardiac or pulmonary disease
      • Diabetes mellitus
      • Asplenia (functional or anatomic)
      • Hemoglobinopathies
      • Congenital immunodeficiencies involving any part of the immune system, including B-lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions
      • Hematopoietic stem cell transplant recipient (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
      • HIV infection
      • Immunosuppressive therapy including use of long-term corticosteroids, post-organ transplant therapy, and certain anti-rheumatic drugs
      • Chronic kidney disease, including nephrotic syndrome
      • Chronic liver disease (including hepatic cirrhosis due to any cause)
      • Solid organ or islet transplant (candidate or recipient)
      • Residents of a personal care home or a long-term care facility OR in residential care due to complex medical needs
      • Persons with alcoholism
      • Persons who are homeless
      • Persons who use illicit drugs
Rabies Vaccine
  • Individuals with occupational risks (including those completing post-secondary practicum) as follows:
    • veterinarians and veterinarian assistants
    • animal health technologists, veterinary technologists, veterinary office assistants
    • taxidermists, trappers, spelunkers
    • individuals working with injured wildlife
    • conservation officers, park rangers, animal control officers
    • laboratory and field personnel working with rabies
    • zoologists or other individuals working in rabies endemic countries
Respiratory Syncytial Virus (RSV)
  • Individuals aged 60 years and older who reside in a personal care home (PCH) are eligible to receive one dose of RSV vaccine. This also includes individuals who reside in a transitional or respite care unit within a PCH facility, who have been paneled for PCH and are awaiting PCH placement.
Rotavirus (Rota)
  • All infants born on or after April 1, 2021, are eligible for two doses of Rot-1 (Rotarix®). The first dose should be given no earlier than 6 weeks of age and before 15 weeks of age, with at least 4 weeks between doses. The administration of both doses must be completed by 8 months.
  • Infants who received Rot-5 (RotaTeq®) and did not complete their three-dose Rot-5 series can complete the series with one or two doses of Rot-1 as needed. These infants should receive three doses of rotavirus vaccine in total, with at least 4 weeks between doses, and with the schedule being completed by 8 months.*

*Whenever possible, the vaccine series should be completed with the same product.

Seasonal Influenza Vaccine
Tetanus and Diphtheria (Td)
  • All individuals ≥ 7 years of age, every 10 years.
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Hypo- or asplenic (Sickle Cell Disease, etc.)
Tetanus, Diphtheria and acellular Pertussis (Tdap)
  • Individuals at 13 to 15 years of age (Grade 8 or 9 school-based program).
  • Individuals who missed the vaccine in Grade 8 or 9 and are born on or after January 1, 1989.
  • Adults who are due for a Td booster and have not previously received a pertussis-containing vaccine in adulthood*.
  • Pregnant women in every pregnancy. Optimal timing is between 27 and 32 weeks gestation, although Tdap vaccine may be given at any time during pregnancy.
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Hypo- or asplenic (Sickle Cell Disease, etc.)

* There is no minimum interval between the Td and Tdap vaccine.

Tetanus, Diphtheria, acellular Pertussis, Inactivated Polio (Tdap-IPV)
  • All children from 4 years of age to < 7 years of age as their pre-school booster. For those 7-18 years of age and not previously immunized please refer to the Recommended Immunization Schedules for those Not Previously Immunized. (www.gov.mb.ca/health/publichealth/cdc/div/not.html).
  • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have the following conditions and have been provided a CCMB directed Immunization Schedule:
    1. Malignant neoplasms (solid tissue and haematological) including leukemia and lymphoma, or clonal blood disorder, and who will receive or have completed immunosuppressive therapy including chemo therapy or radiation therapy, or
    2. Hypo- or asplenic (Sickle Cell Disease, etc.)
Diphtheria, Tetanus. acellular Pertussis, Inactivated Polio (DTaP-IPV)
  • DTaP-IPV is no longer available in Canada once current stock is depleted. It was used in children from 4 years of age to < 7 years who were not previously immunized as part of their primary series. DTaP-IPV-Hib is being used in its place. Please refer to the Recommended Immunization Schedules for those Not Previously Immunized. (www.gov.mb.ca/health/publichealth/cdc/div/not.html)
Varicella (Var)
  • Individuals born during or after 2008 are eligible to receive 2 doses of varicella vaccine at ≥ 12 months of age. (Susceptible individuals born prior to 2008 who have zero doses of varicella vaccine should refer to the Recommended Immunization Schedules for Individuals NOT Previously Immunized.)*
  • Susceptible individuals with at least one of the following high-risk medical conditions may be eligible to receive 2 doses of varicella vaccine after consultation with a specialist with expertise in immunization, immunodeficiency or both (minimum interval between doses is 3 months):
    • Children and adolescents receiving chronic salicylate therapy (acetylsalicylic acid)
    • HIV-infected people who are not severely immunocompromised (CD4 cell count ≥ 200 x 106/L and CD4 percentage ≥15%)
    • Asplenia (functional or anatomic)
    • Chronic renal disease or undergoing dialysis
    • Cystic fibrosis
    • Pre-solid organ transplant (with the second dose given at least 4 weeks prior to transplant)
    • Hematopoietic stem cell transplant recipients (as per CancerCare Manitoba Blood and Marrow Transplant (BMT) Immunization Schedule)
    • Patients currently under the care of a haematologist or oncologist from CancerCare Manitoba (CCMB) who have been provided a CCMB directed Immunization Schedule.

* Minimum intervals vary depending on the age at first dose; please see the Canadian Immunization Guide.

Communicable Disease Control (CDC)
 Public Health
Manitoba Health
4th Floor - 300 Carlton St.
Winnipeg MB  R3B 3M9  CANADA

Health Links – Info Santé
204-788-8200 or 1-888-315-9257